Equities research analysts expect Epizyme, Inc. (NASDAQ:EPZM) to report ($0.68) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Epizyme’s earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.75). Epizyme reported earnings per share of ($0.42) during the same quarter last year, which suggests a negative year over year growth rate of 61.9%. The company is expected to announce its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Epizyme will report full year earnings of ($2.38) per share for the current financial year, with EPS estimates ranging from ($2.67) to ($2.20). For the next financial year, analysts forecast that the business will report earnings of ($2.61) per share, with EPS estimates ranging from ($3.11) to ($2.10). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Epizyme.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The company had revenue of $10 million during the quarter, compared to analysts’ expectations of $3.95 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. The firm’s revenue for the quarter was up 2027.7% on a year-over-year basis.

Several analysts have weighed in on the company. Zacks Investment Research downgraded Epizyme from a “buy” rating to a “hold” rating in a research note on Monday, May 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research note on Friday, May 19th. Wedbush reaffirmed an “outperform” rating and set a $24.00 target price on shares of Epizyme in a research note on Thursday, May 18th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $20.00 target price (up previously from $19.00) on shares of Epizyme in a research note on Wednesday, May 10th. Finally, Cann reaffirmed a “buy” rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, April 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $23.38.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/15/epizyme-inc-epzm-expected-to-post-earnings-of-0-68-per-share.html.

In other news, CFO Andrew E. Singer sold 3,024 shares of the business’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $15.50, for a total value of $46,872.00. Following the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at approximately $628,199.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $16.11, for a total value of $241,650.00. Following the completion of the sale, the insider now directly owns 22,228 shares in the company, valued at approximately $358,093.08. The disclosure for this sale can be found here. Insiders sold a total of 50,524 shares of company stock worth $746,797 in the last three months. Company insiders own 25.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of EPZM. Legal & General Group Plc raised its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Epizyme during the first quarter worth about $175,000. BB&T Securities LLC bought a new stake in shares of Epizyme during the second quarter worth about $181,000. Trexquant Investment LP bought a new stake in shares of Epizyme during the second quarter worth about $184,000. Finally, SG Americas Securities LLC raised its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the period. 81.24% of the stock is currently owned by institutional investors.

Epizyme (EPZM) traded up 0.38% during midday trading on Tuesday, hitting $13.30. The stock had a trading volume of 299,171 shares. Epizyme has a one year low of $7.02 and a one year high of $18.50. The firm’s market cap is $777.60 million. The stock has a 50-day moving average price of $13.73 and a 200 day moving average price of $14.49.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.